Evidence map›Paper›PMID 9774700›Full record

ArticleMolecular and cellular biology1998

Exploring functional redundancy in the immunoglobulin mu heavy-chain gene enhancer.

W Dang, B S Nikolajczyk, R Sen

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Memories of lost enhancers.Genes & development · 2010
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

W DangRosenstiel Research Center and Departments of Biology and Biochemistry, Brandeis University, Waltham, Massachusetts 02254, USA.
B S Nikolajczyk
R Sen
Brandeis University · US

Funding

REGULATION OF IMMUNOGLOBULIN GENE EXPRESSION IN B CELLSR01GM038925 · NIGMS · BRANDEIS UNIVERSITY · PI REN, RUIBAO · 1992 to 2003
$1.2M
FACTORS REGULATING IG GENE EXPRESSION IN B-CELLSR29GM038925 · NIGMS · BRANDEIS UNIVERSITY · PI SEN, RANJAN · 1987 to 1991
–
NIGMS NIH HHS GM 38925NIGMS NIH HHS R01 GM038925
6 · The paper itself

Abstract

Immunoglobulin (Ig) mu heavy-chain gene enhancer activity is mediated by multiple DNA binding proteins. Mutations of several protein binding sites in the enhancer do not affect enhancer activity significantly. This feature, termed redundancy, is thought to be due to functional compensation of the mutated sites by other elements within the enhancer. In this study, we identified the elements that make the basic helix-loop-helix (bHLH) protein binding sites, muE2 and muE3, redundant. The major compensatory element is a binding site for interferon regulatory factors (IRFs) and not one of several other bHLH protein binding sites. These studies also provide the first evidence for a role of IRF proteins in Ig heavy-chain gene expression. In addition, we reconstituted the activity of a monomeric mu enhancer in nonlymphoid cells and defined the domains of the ETS gene required for function.

Indexed as

AnimalsBinding SitesCell LineDNA-Binding ProteinsEnhancer Elements, GeneticGene Expression RegulationHelix-Loop-Helix MotifsHumansImmunoglobulin mu-ChainsInterferon Regulatory Factor-1InterferonsMiceMutationPhosphoproteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-etsDNA-Binding ProteinsImmunoglobulin mu-ChainsInterferon Regulatory Factor-1InterferonsIRF1 protein, humanIrf1 protein, mousePhosphoproteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-etsTranscription Factors

Identifiers

PMID9774700
PMCPMC109270
OpenAlexW1820038702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.